Elsevier

The Lancet

Volume 397, Issue 10279, 20–26 March 2021, Pages 1085-1094
The Lancet

Articles
Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data

https://doi.org/10.1016/S0140-6736(21)00272-5Get rights and content

Summary

Background

In cardiovascular disease, prevention strategies targeting standard modifiable cardiovascular risk factors (SMuRFs; hypertension, diabetes, hypercholesterolaemia, and smoking) are crucial; however, myocardial infarction in the absence of SMuRFs is not infrequent. The outcomes of individuals without SMuRFs are not well known.

Methods

We retrospectively analysed adult patients with first-presentation ST-elevation myocardial infarction (STEMI) using data from the Swedish myocardial infarction registry SWEDEHEART. Clinical characteristics and outcomes of adult patients (age ≥18 years) with and without SMuRFs were examined overall and by sex. Patients with a known history of coronary artery disease were excluded. The primary outcome was all-cause mortality at 30 days after STEMI presentation. Secondary outcomes included cardiovascular mortality, heart failure, and myocardial infarction at30 days. Endpoints were also examined up to discharge, and to the end of a 12-year follow-up. Multivariable logistic regression models were used to compare in-hospital mortality, and Cox-proportional hazard models and Kaplan-Meier analysis for long-term outcomes.

Findings

Between Jan 1, 2005, and May 25, 2018, 9228 (14·9%) of 62 048 patients with STEMI had no SMuRFs reaching diagnostic thresholds. Median age was similar between patients with SMuRFs and patients without SMuRFs (68 years [IQR 59–78]) vs 69 years [60–78], p<0·0001). SMuRF-less patients had a similar rate of percutaneous coronary intervention to those with at least one modifiable risk factor, but were significantly less likely to receive statins, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockade (ARB), or β-blockers at discharge. By 30 days after presentation, all-cause mortality was significantly higher in SMuRF-less patients (hazard ratio 1·47 [95% CI 1·37–1·57], p<0·0001). SMuRF-less women had the highest 30-day mortality (381 [17·6%] of 2164), followed by women with SMuRFs (2032 [11·1%] of 18 220), SMuRF-less men (660 [9·3%] of 7064), and men with SMuRFs (2117 [6·1%] of 34 600). The increased risk of 30-day all-cause mortality in SMuRF-less patients remained significant after adjusting for age, sex, left ventricular ejection fraction, creatinine, and blood pressure, but was attenuated on inclusion of pharmacotherapy prescription (ACEI or ARB, β-blocker, or statin) at discharge. Additionally, SMuRF-less patients had a significantly higher rate of in-hospital all-cause mortality than patients with one or more SMuRF (883 [9·6%] vs 3411 [6·5%], p<0·0001). Myocardial infarction and heart failure at 30 days were lower in SMuRF-less patients. All-cause mortality remained increased in the SMuRF-less group for more than 8 years in men and up to the 12-year endpoint in women.

Interpretation

Individuals who present with STEMI in the absence of SMuRFs have a significantly increased risk of all-cause mortality, compared with those with at least one SMuRF, which was particularly evident in women. The increased early mortality rates are attenuated after adjustment for use of guideline-indicated treatments, highlighting the need for evidence-based pharmacotherapy during the immediate post-infarct period irrespective of perceived low risk.

Funding

Swedish Heart and Lung Foundation, National Health and Medical Research Council (Australia).

Introduction

In coronary artery disease, targeted strategies against the well recognised modifiable risk factors of diabetes, hypercholesterolaemia, hypertension, and smoking (known as the standard modifiable cardiovascular risk factors [SMuRFs])1, 2 have led to major improvements in prevention and treatment. However, a clinically significant proportion of patients present with life-threatening myocardial infarction with no previous symptoms, and none of the SMuRFs at or greater than diagnostic thresholds.3 We have coined the term SMuRF-less4 to raise awareness of this pragmatically challenging group and encourage focused research efforts.

SMuRF-less patients are often overlooked in clinical trial publications, which classically report the proportion of patients with each of the known risk factors, but not the proportion with none. In an initial single-centre retrospective study, we showed that the proportion of patients with ST-elevation myocardial infarction (STEMI) who were SMuRF-less increased, from five (10·9%) of 46 patients in 2006, to 26 (27·4%) of 95 patients by 2014.4 An increase in the proportion of SMuRF-less patients with STEMI was also observed in a large Australian national registry, increasing from 45 (14%) of 337 patients to 132 (23%) of 570 patients between 1999 and 2017.5 This group had a higher in-hospital mortality rate compared with patients with at least one SMuRF,5 similar to previous reports in Canadian and US cohorts.6, 7 This unexpected observation requires further appraisal.

Research in context

Evidence before this study

Patients who present with ST-elevation myocardial infarction (STEMI) without modifiable risk factors are not uncommon. The standard for clinical trials is to report the proportion of patients with standard modifiable cardiovascular risk factors (SMuRFs; diabetes, hypertension, hypercholesterolaemia, and smoking). On a review of the international guidelines and their referenced trials, we found an absence of data on the proportion of patients without SMuRFs. Thus, characteristics and outcomes in this group, including adherence and specific response to secondary prevention therapies, are not known. We recently reported an increase in the proportion of SMuRF-less patients with STEMI in the past decade, and in a national cohort, observed an unexpected excess in in-hospital mortality compared with patients with at least one SMuRF. Longer-term outcomes, particularly those driven by progression of atherosclerosis, are not known.

Added value of this study

This study is unprecedented in examining the characteristics and long-term outcomes in patients presenting with STEMI with no apparent SMuRFs, who are commonly assumed to be at low risk of further complications despite having atherosclerosis and life-threatening myocardial infarction with no obvious explanation. Using the comprehensive SWEDEHEART registry, we examined mortality and major adverse cardiovascular events for up to 12 years of follow-up in patients presenting with STEMI without SMuRFs. We present an unexpected finding of significant excess 30-day mortality in SMuRF-less patients, compared with patients with at least one modifiable risk factor, which would appear to compound the already poor outcomes particularly in women. The association of SMuRF-less status with increased early mortality did not appear to be driven by recurrent myocardial infraction or heart failure, and was attenuated after adjustment for use of guideline-indicated treatments targeting angiotensin and β1-adrenergic neurohormonal pathways. Detailed long-term follow-up of SWEDEHEART data showed that, although progression of atherosclerosis and recurrent myocardial infarction is considerable in patients without SMuRFs, these events are less common than in patients with SMuRFs.

Implications of all the available evidence

Evidence-based pharmacotherapy should be prescribed during the immediate post-infarct period irrespective of perceived low risk. Increased education and awareness are now needed, given that low risk for developing atherosclerosis does not seem to equate to low risk of death or atherosclerotic events after myocardial infarction, and that women without SMuRFs are at the highest risk of mortality in the first 30 days after presentation. SMuRF-less patients should be considered and represented in all clinical trials, and reported alongside the proportion of patients with each individual risk factor. Dedicated meta-analyses of clinical trial data examining the efficacy of secondary prevention pharmacotherapy in SMuRF-less patients would be valuable, and help inform guidelines regarding management of this group. The substantial number of SMuRF-less patients we identified and their high 30-day mortality rate highlights the need to find new biomarkers, to improve early identification and primary prevention of atherosclerosis, where traditional risk algorithms are currently failing.

The Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) captures a large, unbiased population of patients presenting with STEMI,8 providing an unparalleled opportunity to examine contributing factors and outcomes of SMuRF-less patients with STEMI. Data collection has been ongoing since 1995. In this study, we analysed data from patients with first-presentation STEMI to examine the clinical characteristics of patients without SMuRFs, and compare short-term and long-term outcomes with their counterparts with at least one modifiable risk factor.

Section snippets

Study design and population

Patient data from SWEDEHEART were retrospectively examined overall and by sex. Details of the SWEDEHEART national registry have been published previously.8, 9 Briefly, the registry enrols all patients admitted to cardiac care units in Sweden with myocardial infraction. The registry includes data on patient characteristics, medications, and outcomes and data on acute coronary care, coronary interventions, and secondary prevention. The data quality is monitored by a formal audit process.

Results

Between Jan 1, 2005, and May 25, 2018, 74 679 adult patients with STEMI were registered in SWEDEHEART and 62 048 were eligible for inclusion in our study. Our population included 20 384 (32·9%) women and 41 664 (67·1%) men, with a median follow-up of 4·9 years (IQR 1·8–8·5). These patients comprised the population after excluding individuals with a history of coronary artery disease. Of the 62 048 patients, 9228 (14·9%) had no documented SMuRFs (ie, were SMuRF-less) before or during

Discussion

This study of extensive multicentre data highlights the importance of an often overlooked subgroup of patients, who despite having no traditional risk factors, present with STEMI. We used data from one of the largest and most comprehensive registries on heart disease and myocardial infarction globally, with more than 60 000 individuals included in our analysis. We observed that, for SMuRF-less patients, particularly women, in-hospital and 30-day mortality were in substantial excess, versus the

Data sharing

SWEDEHEART does not allow individual data sharing to third parties. Access to aggregated data might be granted following review by the SWEDEHEART steering committee. Such requests can be submitted to the SWEDEHEART steering committee (contact details online) for consideration.

References (24)

  • T Jernberg et al.

    The Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)

    Heart

    (2010)
  • J Harnek et al.

    The 2011 outcome from the Swedish Health Care Registry on Heart Disease (SWEDEHEART)

    Scand Cardiovasc J

    (2013)
  • Cited by (138)

    View all citing articles on Scopus
    View full text